Flush with $5 m, ONL Pushes Forward to Test ONL 1204 as Retinal Detachment Treatment

John Freshley, president and CEO of ONL Therapeutics, updates OIS on the development program of Fas inhibitors. The company’s lead product is ONL 1204, which has orphan drug designation for retinal detachment. ONL recently secured a $5 million Series A financing in May. The company is on track to file an IND next year. Freshley also gives a peak at the company’s glaucoma program.